Literature DB >> 30920215

TRIP-Catalyzed Asymmetric Synthesis of (+)-Yatein, (-)-α-Conidendrin, (+)-Isostegane, and (+)-Neoisostegane.

Peter Hartmann1, Mattia Lazzarotto1, Lorenz Steiner1, Emmanuel Cigan1, Silvan Poschenrieder1, Peter Sagmeister1, Michael Fuchs1.   

Abstract

The asymmetric allylation under the assistance of catalytic amounts of 3,3'-bis(2,4,6-triisopropylphenyl)-1,1'-binaphthyl-2,2'-diyl hydrogen phosphate (TRIP) allows the concise construction of the lignan scaffold from simple aldehydes and allylic bromides with full control of the two formed stereocenters. This young methodology has been employed to synthesize four naturally and pharmaceutically active lignans. Members of the dibenzylbutyrolactone, the tetraline, and the dibenzocyclooctadiene classes have been synthesized in 40-47% overall yield along four-step synthetic routes.

Entities:  

Year:  2019        PMID: 30920215     DOI: 10.1021/acs.joc.9b00065

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  3 in total

Review 1.  Recent strategies and tactics for the enantioselective total syntheses of cyclolignan natural products.

Authors:  Rebekah G Reynolds; Huong Quynh Anh Nguyen; Jordan C T Reddel; Regan J Thomson
Journal:  Nat Prod Rep       Date:  2022-03-23       Impact factor: 13.423

2.  Mechanistic Studies of the TRIP-Catalyzed Allylation with Organozinc Reagents.

Authors:  Peter E Hartmann; Mattia Lazzarotto; Jakob Pletz; Stefan Tanda; Philipp Neu; Walter Goessler; Wolfgang Kroutil; A Daniel Boese; Michael Fuchs
Journal:  J Org Chem       Date:  2020-07-22       Impact factor: 4.354

3.  Chemoenzymatic Total Synthesis of Deoxy-, epi-, and Podophyllotoxin and a Biocatalytic Kinetic Resolution of Dibenzylbutyrolactones.

Authors:  Mattia Lazzarotto; Lucas Hammerer; Michael Hetmann; Annika Borg; Luca Schmermund; Lorenz Steiner; Peter Hartmann; Ferdinand Belaj; Wolfgang Kroutil; Karl Gruber; Michael Fuchs
Journal:  Angew Chem Int Ed Engl       Date:  2019-05-08       Impact factor: 15.336

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.